Japan Tirabrutinib Approval Breaks New BTK Ground In Lymphoma
Latuda Also Gets Delayed Nod
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Scrip spoke with Sumitovant CEO Myrtle Potter about short- and long-term goals for the portfolio of five companies, including Myovant, Urovant and Enzyvant with potential near-term approvals.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.